Method of producing a nucleic acid encoding an antibody
An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells. The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.
1. A method of producing a nucleic acid encoding an antibody or antigen-binding portion thereof, wherein the method comprises the steps of:
(a) transplanting a lesion tissue comprising infiltrating lymphocytes into a highly immunodeficient non-human animal, wherein the animal is not a SCID (severe combined immunodeficient) mouse;
(b) detecting the proliferation of plasma cells at the site of transplantation;
(c) recovering a sample of the lesion tissue from the site of transplantation, wherein the sample comprises plasma cells; and
(d) obtaining a nucleic acid encoding an antibody or an antigen-binding portion thereof from the recovered sample of lesion tissue, wherein the antibody binds to an antigen of the lesion tissue.
2. The method of production of claim 1 , wherein step (d) comprises excising plasma cells from the sample of lesion tissue and collecting nucleic acids encoding antibodies from the excised plasma cells.
3. The method of claim 1 , wherein step (d) further comprises:
amplifying a nucleic acid encoding an antibody variable region using (i) the nucleic acid encoding an antibody or a antigen-binding portion thereof as a template and (ii) an oligonucleotide capable of amplifying the antibody variable region.
4. The method of claim 1 , wherein the transplanted lesion tissue comprises cancer cells, hyperplasia cells, or virus-infected cells.
5. The method of claim 4 , wherein the transplanted lesion tissue comprises cells of a solid cancer or a blood cancer.
6. The method of claim 5 , wherein the transplanted lesion tissue comprises cells of a solid cancer that is a prostate cancer, stomach cancer, breast cancer, lung cancer, liver cancer, colorectal cancer, or pancreatic cancer.
7. The method of claim 4 , wherein the transplanted lesion tissue comprises cells of a benign prostatic hyperplasia.
8. The method of claim 1 , wherein the highly immunodeficient non-human animal lacks NK cells.
9. The method of claim 1 , wherein the highly immunodeficient non-human animal lacks T cells, B cells, and NK cells.
10. The method of claim 1 , wherein the lesion tissue is from a human subject.
11. The method of claim 1 , wherein the antibody is a human antibody.
12. The method of claim 1 , further comprising expressing a polypeptide comprising the antibody or portion thereof and testing whether the antibody or portion thereof binds to an antigen of the lesion tissue or an antigen of a cancer cell.
13. The method of claim 1 , wherein the antibody is an IgG.
14. The method of claim 1 , wherein the antibody is an IgM.
15. The method of claim 1 , wherein the antibody or portion thereof is an Fab, F(ab')2, or Fv.
16. The method of claim 1 , wherein the antibody or portion thereof is a single chain Fv (scFv).
17. The method of claim 1 , wherein step (b) comprises determining the level of human antibodies in the serum of the animal, with a higher level of human antibodies in the serum being an indication of a higher number of plasma cells at the site of transplantation.